Research
JDRF is the worldwide leader for research to cure type 1 diabetes.
JDRF’s mission is to find a cure for diabetes and its complications through the support of research. JDRF is also committed to developing new and better treatments that improve the lives of people with type 1 diabetes in the near term and keep them healthy while we advance toward a cure.
JDRF Research Funding Facts
- Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has funded more than $1.4 billion in research. In FY2009 alone, JDRF funded nearly $101 million, more than $42 million of which represented new scientific projects.
- In a typical year, 85 percent of JDRF’s expenditures directly support research and research-related education.
- In FY2009, JDRF funded research projects in 22 countries, including more than 40 human clinical trials.
JDRF’s Research Goals
JDRF is committed to aggressively following the most promising paths to cure, better treat, and prevent type 1 diabetes. We are targeting our resources on science that seeks to:
- Arrest the immune attack on the insulin-producing beta cells
- Restore or replace beta cell function
- Better control blood sugar levels
- Protect people from – or reverse – complications
FY2009 JDRF Research Funding
Immune Therapies |
$33 million |
Beta Cell Therapies |
$39.8 million |
Glucose Control |
$5.9 million |
Complications Therapies |
$22.1 million |
Total |
$100.8 million |
Download JDRF Research Funding Facts
|
Stop the AttackThis area focuses on ways to stop the immune system attack on the body’s insulin-producing beta cells that causes type 1 diabetes. Within this area, JDRF is prioritizing antigen-specific therapies that would reverse the immune attack in type 1 diabetes without suppressing the entire immune system. |
|
Tight ControlThis area seeks to identify ways to dramatically improve blood glucose control while avoiding dangerous highs and lows in people at all stages of type 1 diabetes. JDRF is prioritizing the development of a closed loop artificial pancreas, a device combining glucose monitors and insulin pumps, to enable people to achieve tight blood sugar control and reduce their risk of complications. JDRF is also prioritizing the development of novel insulins that are glucose-responsive, faster-acting, easier to use, and more effective. |
|
Restore Beta CellsThis area aims to find ways to restore the body’s ability to make insulin through the:
JDRF is prioritizing regeneration because of its potential to restore beta cell function in the largest number of people living with type 1 diabetes. |
|
Prevent, Stop, ReverseThis area seeks to identify ways to dramatically improve blood glucose control while avoiding dangerous highs and lows in people at all stages of type 1 diabetes. JDRF is prioritizing the development of a closed loop artificial pancreas, a device combining glucose monitors and insulin pumps, to enable people to achieve tight blood sugar control and reduce their risk of complications. JDRF is also prioritizing the development of novel insulins that are glucose-responsive, faster-acting, easier to use, and more effective. |
To help you better understand what is involved in participating in a clinical trial, and to simplify the process of finding trials that are of interest to you (or your child), JDRF has created an online customized clinical trials listing service - the JDRF Clinical Trials Connection.
Please “Save the Date” for this ground-breaking summit featuring four perspectives on translational medicine, innovation and industry.
Enter your e-mail below and click GO to sign up for the JDRF Bay Area e-Newsletter.
As the leading charitable funder of diabetes research worldwide, the Juvenile Diabetes Research Foundation International offers a wide variety of grants and fellowships to qualified diabetes researchers.
Visit the JDRF International website to learn more.
49 Stevenson St. Suite 1200, San Francisco, CA 94105
Phone: (415) 977-0360
E-mail:
Website: http://www.jdrfbayarea.org